MYOMETRIAL ELASTOGRAPHY AS A POTENTIAL MARKER OF PROGESTIN RESISTANCE IN ADENOMYOSIS

Review OA: green CC0
⚙ AI-generated summary by qwen3.7-flash, 2026-10-14 ⓘ

This thesis reviews 2022–2025 studies showing that higher adenomyotic lesion stiffness correlates with dysmenorrhoea severity and dienogest treatment relapse, supporting elastography as a potential marker of progestin resistance.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-10-14 · read from full text ⓘ

This thesis reviews studies from 2022 to 2025 investigating ultrasound elastography as a method to identify progestin resistance in women with adenomyosis. The analysis indicates that adenomyotic lesions exhibit higher stiffness and increased fibrosis marker expression compared to normal myometrium, which correlates with dysmenorrhea severity. Higher lesion stiffness was specifically associated with symptom relapse after six months of dienogest treatment, although no predictive stiffness threshold has been established. This paper is centrally about adenomyosis — specifically evaluating myometrial elastography as a potential biomarker for predicting poor response to progestin therapy.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Some women with adenomyosis respond poorly to progestins, and conventional grey-scale ultrasound cannot reliably identify them before treatment. This thesis reviews studies published in 2022–2025 on ultrasound elastography of adenomyotic lesions. Lesion stiffness is higher than that of normal myometrium, is accompanied by higher expression of fibrosis markers and correlates with the severity of dysmenorrhoea. In women treated with dienogest for six months, higher lesion stiffness was associated with symptom relapse after treatment was stopped. No study has yet reported a stiffness threshold that predicts insufficient response during treatment. Elastography therefore deserves evaluation as a component of prognostic models of response to progestin therapy.
Full text 978 characters · extracted from oa-doi-fallback · click to expand
Published October 10, 2026 | Version v1 Journal article Open MYOMETRIAL ELASTOGRAPHY AS A POTENTIAL MARKER OF PROGESTIN RESISTANCE IN ADENOMYOSIS Authors/Creators - 1. Tashkent State Medical University Description Some women with adenomyosis respond poorly to progestins, and conventional grey-scale ultrasound cannot reliably identify them before treatment. This thesis reviews studies published in 2022–2025 on ultrasound elastography of adenomyotic lesions. Lesion stiffness is higher than that of normal myometrium, is accompanied by higher expression of fibrosis markers and correlates with the severity of dysmenorrhoea. In women treated with dienogest for six months, higher lesion stiffness was associated with symptom relapse after treatment was stopped. No study has yet reported a stiffness threshold that predicts insufficient response during treatment. Elastography therefore deserves evaluation as a component of prognostic models of response to progestin therapy.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

openalex
last seen: 2026-11-16T06:03:07.005966+00:00
License: CC0 · commercial use OK